Orthocell Limited announced the appointment of Dr. Jonathan Bell to its Medical and Scientific Advisory Board (MSAB). The appointment of UK orthopaedic surgeon, Dr. Bell follows the recent successful CelGro® tendon study results announced on 6 June 2018 and ensures Orthocell is well positioned to expand CelGro® indications into the orthopaedic field (including bone, tendon, nerve and cartilage regeneration procedures), whilst simultaneously executing its near term market entry plans for oral bone and soft tissue repair. Orthocell intends to leverage this appointment, clinical results and existing European approval for orthopaedic regulatory submissions in key regions including the US, Europe and Australia.